Second generation antipsychotics: Evolution of scientific knowledge or uncovering fraud

Epidemiology and Psychiatric Sciences

Volumn 22, Issue 3, 2013, Pages 235-237

  Rosenheck, R ^a   Cheng, F ^b   Jones, P B ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Antipsychotic drugs; pharmaceutical marketing; psychopharmacology; schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; SECOND GENERATION ANTIPSYCHOTIC AGENT; UNCLASSIFIED DRUG;

COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; EVIDENCE BASED PRACTICE; GOVERNMENT; LAW SUIT; MENTAL HEALTH CARE PERSONNEL; NOTE; PHYSICIAN; UNITED STATES; FRAUD; HUMAN; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; FRAUD; HUMANS; SCHIZOPHRENIA;

EID: 84882409893     PISSN: 20457960     EISSN: 20457979     Source Type: Journal    
DOI: 10.1017/S2045796012000662     Document Type: Note

References (15)

1. Almashat S, Preston C, Waterman T, Wolfe S, Public Citizen's Health Research Group (2010). Rapidly Increasing Criminal and Civil Monetary Penalties Against the Pharmaceutical Industry: 1991 to 2010. Retrieved 12 October 2011 from http://www.citizen.org/documents/ rapidlyincreasingcriminalandcivilpenalties.pdf
2. Breier A (2011). Anxiety disorders and antipsychotic drugs: A pressing need for more research. American Journal of Psychiatry 168, 1012-1014.
3. Berenson A (2006). Eli Lilly Said to Play Down Risk of Top Pill. New York Times, 17 December 2006. Retrieved 12 October 2011 from http://www.nytimes.com/ 2006/12/17/business/17drug.html?pagewanted=all
4. Business Week (2012a). Arkansas judge fines J&J 1.1B in Risperdal case. Business Week, April 2012. Retrieved 30 October 2011 from http://www.businessweek.com/ap/2012-04/D9U31A8O1.htm
5. BusinessWeek (2012b). J&J Said to Agree to 2.2 Billion Drug Marketing Accord. Business Week, June 2012. Retrieved 30 October 2011 from http://www.businessweek.com/news/2012-06-11/j-and-j-said-to-pay-2-dot-2-billion- to-endrisperdal-sales-probe
6. Comer JS, Mojtabai R, OlfsonM(2011). National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. American Journal of Psychiatry 168, 1057-1065
7. Hausman K (2009). Industry-supported symposia to be phased out. Psychiatry News 44, 4.
8. IMS Health, 2012. http://www.imshealth.com/ims/Global/Content/Corporate/ Press%20Room/Top-line%20Market%20Data/2008%20Top-line%20Market%20Data/ Global-Top-15-Therapy-Classes.pdf
9. Leslie D & Rosenheck RA (2012). Off-label use of antipsychotic medications in Medicaid. American Journal of Managed Care 18, e109-e117.
10. Leslie DL, Mohamed S, Rosenheck RA (2009). Off-label use of antipsychotic medications in the Department of Veterans Affairs. Psychiatric Services 60, 1175-1181.
11. Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Freedman R (2006). Conflict of interest. American Journal of Psychiatry 163, 571-573.
12. Rosenheck RA (2005). The growth of psychopharmacology in the 1990s: evidence-based practice or irrational exuberance. International Journal of Law and Psychiatry 28, 467-483.
13. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association 290, 2693-2702.
14. Tollefson GD, Beasley Jr CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154, 457-465.
15. US Department of Justice (2009). Eli Lilly and Company Agrees to Pay 1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa. Retrieved 30 October 2012 from http://www.justice.gov/opa/pr/2009/January/09- civ-038.html